Mitigating Risks in Biotechs

The Life Sciences Report | |

Griffin Securities has assembled a biotech portfolio weighted toward companies pursuing high-science therapeutic approaches. However, as analyst Keith Markey explains, through a combination of

How the Lack of R&D at Big Pharma Is Boosting Small Biotechs

The Life Sciences Report | |

The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview

Biotech Investors Need to Focus on Catalysts

The Life Sciences Report | |

When progress is made in drug development, value is created. Investors recognize that progress by purchasing shares in companies when milestones—which act as catalysts—are met. The

Equities Sector Coverage: Stocks Show Mixed Bag as Investors Get Defensive

Sector Recap | |

Asian stocks were lower on Monday. The Nikkei 225 ended their session at 9,471 – down 1.74% on the day. The Hang Seng ended their session at 20,611 – down 0.44% on the day. European stocks

Equities Sector Coverage: Stocks Up on Three-Year Anniversary of Recession Bottom

Sector Recap | |

The Nation's international trade deficit in goods and services increased to $52.6 billion in January from $50.4 billion (revised) in December. Nonfarm payroll employment rose by 227,000 in

Back to Blue Chips

Brittney Barrett | |

After a broad blue chips decline at the height of the recent volatility, many investors have avoided reclaiming these large cap power houses for fear of what the market may do next. The slide


Symbol Last Price Change % Change






What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.